<DOC>
	<DOCNO>NCT01689987</DOCNO>
	<brief_summary>This phase I trial study side effect best dose hydroxychloroquine give together cyclophosphamide , dexamethasone , sirolimus treat patient multiple myeloma come back period improvement respond treatment . Biological therapy , hydroxychloroquine , may stimulate immune system different way stop cancer cell grow . Sirolimus may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cyclophosphamide dexamethasone , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving hydroxychloroquine together sirolimus , cyclophosphamide , dexamethasone may better treatment multiple myeloma .</brief_summary>
	<brief_title>Hydroxychloroquine , Cyclophosphamide , Dexamethasone , Sirolimus Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) hydroxychloroquine ( HCQ ) combination rapamycin ( sirolimus ) infusional cyclophosphamide pulse dexamethasone ( cy/dex ) patient relapsed/ refractory multiple myeloma . SECONDARY OBJECTIVES : I . To evaluate biological activity efficacy combination cyclophosphamide , dexamethasone , rapamycin hydroxychloroquine patient relapsed/refractory multiple myeloma . II . To determine whether treatment regimen result mammalian target rapamycin ( mTOR ) autophagy inhibition primary myeloma cell therapy corresponds treatment response . OUTLINE : This dose-escalation study hydroxychloroquine . Patients receive hydroxychloroquine orally ( PO ) daily day 1-28 ( day 5-28 course 1 ) , sirolimus PO day -2 4 , cyclophosphamide intravenously ( IV ) continuously dexamethasone PO day 1-4 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 12 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Histologically confirm multiple myeloma Documented relapse persistent disease least 1 prior therapy contain bortezomib lenalidomide ; least 2 prior therapy contain bortezomib one lenalidomide , intolerant bortezomib and/or lenalidomide ; prior autologous allogeneic bone marrow transplantation allow Need treatment myeloma , determine patient 's treating physician ; define progression clinical feature ( worsen anemia , renal function , bone disease , hypercalcemia , recurrent infection , constitutional symptom ) OR biochemical progression ( increase Mspike serum urine , involve serum urine free light chain 2 consecutive time point great 4 week apart ) Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Ability understand willingness sign write informed consent document Birth control require full barrier contraceptive complete abstinence duration time receive therapy 6 month complete last drug take The need treatment : define progression clinical feature ( worsen anemia , renal function , bone disease , hypercalcemia , recurrent infection , constitutional symptom ) OR biochemical progression ( increase Mspike serum urine , involve serum urine free light chain 2 consecutive time point great 4 week apart ) History allergic reaction compound similar chemical biological composition rapamycin hydroxychloroquine Patients may take follow medication study , consider eligible medication discontinue least 72 hour ( hr ) prior first dose Rapamycin : Carbamazepine Rifabutin Rifampin Rifapentine St. John 's wort Clarithromycin Cyclosporine Diltiazem Erythromycin Itraconazole Fluconazole Ketoconazole Telithromycin Verapamil Voriconazole Posaconazole Known macular degeneration retinopathy ( diabetic otherwise ) , porphyria , psoriasis ( wellcontrolled psoriasis allow provide care specialist agree monitor patient exacerbation ) Absolute neutrophil count ( ANC ) = &lt; 1.0 x 10^9/L Platelets = &lt; 50 x 10^9/L reason Serum creatinine &gt; = 2.5 mg/dL Total direct bilirubin &gt; = 2.0 mg/dL Transaminases 2 x upper limit normal Fasting glucose &gt; = 200 mg/dL Serum potassium &lt; 3.4 mmol/l Serum phosphorus &lt; 2.4 mg/dl Other condition would require therapy hydroxychloroquine , include limited , follow : Systemic lupus Rheumatoid arthritis Porphyria cutanea tarda Malaria treatment prophylaxis Evidence active malignancy , except : Basal cell squamous cell carcinoma skin Treated carcinoma situ Uncontrolled intercurrent illness include , limited , follow : Uncontrolled ongoing infection Human immunodeficiency virus ( HIV ) Hepatitis B infection Known glucose6phosphate dehydrogenase ( G6PD ) deficiency Symptomatic congestive heart failure Unstable angina pectoris Uncontrolled cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement Active graftversushost disease ( GvHD ) Inability understand unwillingness sign inform consent document Concurrent antimyeloma therapy within : 7 day prior corticosteroid 14 day prior antimyeloma agent , include thalidomide lenalidomide 28 day different investigational regimen 14 day radiation Women childbearing unwilling unable use acceptable method avoid pregnancy entire study period 30 day last dose study drug Women pregnant breastfeed History G6PD deficiency Known history HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>